As the political winds shift on a whim and public distrust of the pharma industry reaches fever pitch over drug pricing, ...

Based on new data, argenx expects to file for the expansion of Vyvgart’s label into patients with generalized myasthenia ...

Generate:Biomedicines’ Nicole Clouse is one of the key legal minds trying to understand who owns what AI creates. The answers ...

During the COVID-19 pandemic, Health Secretary Robert F. Kennedy Jr.—along with FDA Commissioner Marty Makary and CBER ...

If the trend holds, IQVIA expects 2025 deal volume between Chinese and multinational companies to easily eclipse the 100 ...

The White House has denied reports that the government could soon ban COVID-19 vaccines, noting that in the absence of an ...

Scott Gottlieb, who served as FDA commissioner during the first Trump administration, wrote in a JAMA editorial that China is ...

The MIT professor of management, who already sits on the CDC's revamped immunization advisory committee, is a known skeptic ...

While Truist Securities analysts said the results from the ATTAIN-2 trial leave “room for competition," they also pointed to ...

Regeneron’s cemdisiran, used alone or in combination with its complement inhibitor Veopoz, significantly improved activities ...

AMX0035—approved as Relyvrio in 2022 for amyotrophic lateral sclerosis but voluntarily pulled from the market last year—was ...

The FDA recommends that companies use overall survival as a primary endpoint for clinical trials where feasible. The new ...